Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3716 - Prognostic factors for predicting early recurrence within the first year of surgery in pancreatic ductal adenocarcinoma

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Naru Kim

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

N. Kim, S.H. shin, Y. Ryu, I.W. Han, J.S. Heo, D.W. Choi

Author affiliations

  • Surgery, Samsung Medical Center (SMC), 135-710 - Seoul/KR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3716

Background

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis and it is a lethal disease with a recurrence rate of almost 50% within 1 year even after curative resection. The purpose of this study was to find out risk factors of early recurrence within the first year of surgery in PDAC.

Methods

From January 2007 to December 2016, 833 patients who underwent pancreatectomy with curative intention for PDAC at a single institute were included in this study, and their medical records were retrospectively reviewed.

Results

The median overall survival (OS) was 22.1 months and the median disease free survival(DFS) was 10.4 months. The 5-year OS rate was 25.9% and DFS rate was 18.6%. After excluding 80 patients who have lost to follow-up, there were 394 patients (54.0%) who have recurred within the first year of surgery. Multivariable logistic regression revealed that the followings were independently associated with early recurrence: neutrophil to lymphocyte ratio > 2.7 (odds ratio [OR] 1.684, 95% confidence interval [CI] 1.164 - 2.436), poorly or un-differentiated tumor(OR 2.421, 95% CI 1.678 - 3.492), T stage (T2 [OR 2.082, 95% CI 1.384 - 3.134], T3 [OR 4.577, 95% CI 2.589 - 8.091]), and N stage (N1 [OR 1.560, 95% CI 1.075 - 2.265], N2 [OR 4.561, 2.831 - 7.348]). Adjuvant chemoradiation therapy was a factor that reduces the risk of early recurrence (OR 0.552, 95% CI 0.386 - 0.789).

Conclusions

Identification of risk factors associated with early recurrence in the preoperative and postoperative state may help establish therapeutic strategies to reduce the recurrence rate and improve survival of PDAC patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.